Trademarkia Logo

Canada

C$
Trademark Search in Canada
mRNACT

View On IC.GC.CA

mRNACT
ADVERTISED

on 12 Feb 2025

Last Applicant/ Owned by

Seqirus Inc.

475 Green Oaks ParkwayHolly Springs NC 27540

US

Serial Number

2184878 filed on 28th Oct 2021

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 2600, 160 ELGIN STREETOTTAWA

ONTARIO

CA

K1P1C3

mRNACT

Trademark usage description

medical, biological, and pharmaceutical preparations for scientific and research use, and for the manufacture of pharmaceuticals, namely, bio-chemical Read More

Classification Information

Class [001]
Medical, biological, and pharmaceutical preparations for scientific and research use, and for the manufacture of pharmaceuticals, namely, bio-chemical preparations containing messenger RNA for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research and medical research, namely, bio-chemical preparations for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory and medical research use in the form of active chemical ingredients for use in the manufacture of drug delivery pharmaceuticals.

Classification kind code

11

Class [005]
Vaccines for human use; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing and treating COVID-19, coronavirus disease and respiratory disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ prevention and treatment of COVID-19, coronavirus disease, and respiratory disorders; lipid nanoparticles for pharmaceutical, medical and diagnostic purposes, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals to treat COVID-19, coronavirus disease, and respiratory disorders; drug carriers for medical use, namely, lipid nanoparticles for delivering drugs; lipid nanoparticles for drug delivery sold as an integral component of drugs; pharmaceutical preparations, namely, messenger RNA and delivery agents comprised of lipid nanoparticle tablets and polymer capsules for the delivery of mRNA to human cells; medical, biological, and pharmaceutical preparations for medical laboratory use, namely, preparations containing messenger RNA for preventing and treating COVID-19, coronavirus disease and respiratory disorders.

Classification kind code

11

Class [042]
Pharmaceutical research and development; medical research services; biotechnology research, namely, research and development in the medical biotechnology field; scientific research for medical purposes in the fields of COVID-19, coronavirus disease, and respiratory disorder; design and development of medical technology, namely, development of pharmaceutical preparations and medicines; design, engineering, research, and development services in the field of nucleic acid sequencers for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines.

Classification kind code

11

Class [044]
Medical services, namely, conducting of medical examinations; providing medical information in the field of medical treatment services; providing medical information in the field of medical treatment services via a website.

Classification kind code

11

Mark Details

Serial Number

2184878

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 22
on 5th Sept 2023		Search Recorded
Submitted for opposition 20
on 5th Sept 2023		Examiner's First Report
Submitted for opposition 48
on 31st Aug 2023		Agent Changed
Submitted for opposition 256
on 13th Mar 2023		Notification of Possible Opposition Sent
Submitted for opposition 48
on 12th Jul 2022		Agent Changed
Submitted for opposition 257
on 12th May 2022		Designation Notification - Madrid Protocol
Submitted for opposition 1
on 11th May 2022		Created
Submitted for opposition 31
on 11th May 2022		Formalized
Submitted for opposition 30
on 28th Oct 2021		Filed
Submitted for opposition 228
on 28th Oct 2021		International Registration